Sanstar 2026 EGM clears ₹198 crore Ingredion deal

What shareholders approved on June 20

Sanstar Limited shareholders approved a preferential issue of 1,80,24,157 equity shares to Corn Products Development Inc., an Ingredion group company. The allotment price was set at ₹110 per share, taking the total consideration to about ₹198 crore. The resolution was passed at an Extra-Ordinary General Meeting (EGM) held on June 20, 2026 through video conferencing/other audio visual means (VC/OAVM). Post-issue, the investor is expected to hold around 9% of Sanstar’s post-issue share capital. The company also stated that the investment will not change management or control.

Why the company is raising this capital

Sanstar said the proceeds will be used primarily for working capital requirements and general corporate purposes. At the EGM, Joint Managing Director Mr. Sambhav Gautam Chowdhary communicated this intended use of funds to members. In the published fund deployment split, ₹149.20 crore is earmarked for working capital and ₹49.07 crore for general corporate purposes, with deployment expected in FY 2026-27. Sanstar appointed Acuité Ratings & Research Limited as the monitoring agency for the issue.

Special rights granted to the investor

Along with the share issuance, shareholders approved the grant of special rights to the proposed allottee under Regulation 31B of SEBI (LODR) Regulations, 2015. These rights include the ability to nominate one non-executive, non-independent director to Sanstar’s Board. The investor also received pre-emptive rights to subscribe to additional equity shares. Sanstar disclosed that the investor will also have consultation, affirmative voting, and information rights on specified matters. The company indicated that these rights are part of the transaction documentation and governance covenants, while reiterating that management control remains unchanged.

Voting process and disclosure timeline

Sanstar provided a remote e-voting window ahead of the EGM. Remote e-voting began on June 17, 2026 at 9:00 a.m. IST and ended on June 19, 2026 at 5:00 p.m. IST. Shareholders eligible to vote were those on record as of the cut-off date of June 15, 2026. Members attending the EGM were also allowed to vote during the meeting. Sanstar said consolidated voting results would be declared within prescribed timelines and submitted to BSE Limited and the National Stock Exchange of India Limited (NSE).

Regulatory steps that still need completion

Even after shareholder approval, the preferential allotment remains subject to compliance steps and approvals. The company noted it must meet regulatory conditions including filing a listing application within 20 days of allotment. It also referenced the need to obtain required statutory approvals from SEBI, RBI, and MCA, where applicable. Separately, Sanstar disclosed it has received in-principle approval from BSE and NSE for the preferential issue.

The broader corporate actions tied to the EGM

Apart from the preferential issue, Sanstar’s EGM agenda included corporate actions that support the fundraise and future expansion plans. The company sought approval to increase authorised share capital from ₹38 crore to ₹50 crore. It also proposed amendments to its Memorandum of Association to broaden the object clause. Sanstar additionally referenced updates to constitutional documents to align with the shareholders’ agreement terms connected to the investor’s special rights.

Joint venture plans with Ingredion India and Amishi Drugs

Alongside the equity investment, Sanstar has disclosed plans for a joint venture structure involving Ingredion India Private Limited and Amishi Drugs and Chemicals Private Limited. The JV vehicle referenced is Spark Ingredients Private Limited, where Sanstar will hold a 30% stake. The JV is intended to focus on specialty pharmaceutical excipients and other specialty ingredient products. Sanstar has indicated a 30-36 month timeline for the JV’s commercial operations target after incorporation.

Stock and market context around the announcement

Sanstar’s disclosures came alongside regular market updates around the EGM timeline. On June 19, 2026 at 15:54, Sanstar’s share price was reported at ₹116.45, up ₹1.16 (1.33%) for the day. The preferential issue price of ₹110 per share was disclosed as including a premium of ₹108. While the issue introduces a new strategic shareholder, Sanstar has explicitly stated the investment does not change its management control.

Key facts table

Why this matters for investors

The transaction combines a sizeable equity infusion with governance protections for the incoming strategic investor. For Sanstar, the disclosed fund use points to near-term balance sheet support through working capital, rather than a narrowly earmarked capex-only raise. For the investor, the package of board nomination and affirmative rights indicates a structured approach to oversight without taking control, consistent with the company’s statement that management control will not change. The parallel JV plan adds an additional strategic layer, with a stated focus on specialty pharmaceutical excipients and specialty ingredients, and a defined timeline for commercial operations.

What to watch next

The next milestones are procedural and regulatory. Sanstar will need to complete the allotment process and meet post-allotment requirements, including the listing application within the stated timeline and receipt of applicable statutory approvals. Investors will also track the company’s disclosures on final voting results filings with exchanges and any updates on the JV entity’s incorporation and progress against the stated 30-36 month commercial operations target.